Your browser is no longer supported. Please, upgrade your browser.
Settings
ORMP Oramed Pharmaceuticals Inc. daily Stock Chart
ORMP [NASD]
Oramed Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-0.86 Insider Own1.10% Shs Outstand13.28M Perf Week-2.65%
Market Cap77.95M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float9.57M Perf Month-5.02%
Income-11.20M PEG- EPS next Q- Inst Own10.00% Short Float2.24% Perf Quarter-2.49%
Sales1.30M P/S59.96 EPS this Y-29.90% Inst Trans-3.84% Short Ratio9.71 Perf Half Y-25.41%
Book/sh1.82 P/B3.23 EPS next Y- ROA-27.60% Target Price18.00 Perf Year-9.83%
Cash/sh2.27 P/C2.59 EPS next 5Y- ROE-39.40% 52W Range5.70 - 10.51 Perf YTD-4.08%
Dividend- P/FCF9.28 EPS past 5Y-24.70% ROI-43.30% 52W High-44.15% Beta0.82
Dividend %- Quick Ratio6.40 Sales past 5Y- Gross Margin45.90% 52W Low2.98% ATR0.17
Employees12 Current Ratio6.40 Sales Q/Q- Oper. Margin- RSI (14)36.60 Volatility2.67% 3.07%
OptionableYes Debt/Eq0.00 EPS Q/Q3.30% Profit Margin- Rel Volume0.73 Prev Close5.93
ShortableYes LT Debt/Eq0.00 EarningsApr 12 Payout- Avg Volume22.08K Price5.87
Recom2.00 SMA20-3.01% SMA50-5.74% SMA200-15.96% Volume16,225 Change-1.01%
May-26-16Reiterated FBR Capital Outperform $15 → $20
Dec-01-15Reiterated H.C. Wainwright Buy $24 → $25
Nov-19-15Initiated FBR Capital Outperform $15
Apr-13-15Resumed MLV & Co Buy $27 → $30
Jan-30-14Reiterated Aegis Capital Buy $30 → $35
Jan-08-14Reiterated Aegis Capital Buy $25 → $30
Jan-08-14Initiated MLV & Co Buy $27
Dec-03-13Initiated Aegis Capital Buy $25
Mar-22-17 08:45AM  Oramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017 PR Newswire
Mar-21-17 09:28AM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:45AM  Oramed Appoints Dr. Ronald Law as Chief Strategy Officer PR Newswire
Feb-09-17 05:16PM  While Big Diabetes Stagnates, Smaller Companies Are Moving Faster Than Ever
Feb-07-17 08:30AM  Oramed to Present at BIO CEO and Investor and Disruptive Growth and Healthcare Conferences PR Newswire
Jan-18-17 01:04PM  ORAMED PHARMACEUTICALS INC. Financials
Jan-12-17 05:00AM  Oramed reports 1Q loss
Jan-11-17 05:20PM  ORAMED PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report
Dec-30-16 11:15AM  3 Sleeper Biotechs That Could Bounce Back Strong in 2017
Dec-23-16 12:41PM  Something Strange Is Going On With Oral Insulin
Nov-30-16 02:15PM  ORMP: Oramed Reports Positive Phase Ib Data for ORMD-0901
Nov-29-16 08:30AM  Oramed's ORMD-0901 (Oral GLP-1 Analog) Found Safe and Well Tolerated in Phase Ib Study PR Newswire
Nov-25-16 11:17AM  ORAMED PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report
Oct-06-16 08:45AM  Oramed Receives Additional $4 Million Milestone Payment From HTIT PR Newswire
Sep-19-16 09:00AM  Oramed to Present at the Aegis Capital Growth Conference PR Newswire
Sep-09-16 01:50PM  Inside The FDA: Eli Lilly and Co (LLY) Jardiance Aims at Proving Cardiovascular Benefit in Diabetes, Will FDA Agree? at Insider Monkey
Sep-07-16 08:00AM  Oramed to Present at the Rodman & Renshaw Global Investment Conference PR Newswire
Sep-06-16 01:38PM  Inside the FDA: Why Sanofi SA (ADR) (SNY) IGlarLixi Was Delayed But Novo Nordisk A/S (ADR) (NVO) IDegLira Wasnt at Insider Monkey
Aug-31-16 04:25PM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a
Aug-26-16 08:20AM  Sanofi Just Cant Catch a Break, Knocking at Major Support Again at 24/7 Wall St.
Aug-11-16 11:30AM  Oramed (ORMP) Reports Additional Positive Data from Phase IIb ORMD-0801 Study
Aug-09-16 12:12PM  The Cryptic World of Oral Insulin, Novo Nordisk A/S (ADR) (NVO) vs Oramed Pharmaceuticals, Inc. (ORMP) at Insider Monkey
Aug-05-16 12:35PM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
05:20AM  Novo's insulin pill shows promise in mid-stage trial
Aug-02-16 09:00AM  Oramed Receives Additional $4 Million Milestone Payment From HTIT PR Newswire
Jul-28-16 04:33PM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events
08:15AM  Oramed Reports Additional Phase IIb Oral Insulin Study Data Demonstrating Significant Lowering of Glucose Levels vs Placebo PR Newswire
Jul-27-16 10:15AM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Jul-26-16 09:00AM  Oramed Appoints Dr. Roy Eldor as Chief Medical Director PR Newswire
Jul-06-16 04:58PM  Oramed reports 3Q loss
03:35PM  ORAMED PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report
Jun-22-16 12:20PM  The Top Four Diabetes Best Sellers and One Oral Insulin Pill That May Threaten Them All at Insider Monkey
Jun-21-16 09:05AM  Oramed Announces $6.5 Million Milestone Payment from HTIT PR Newswire
Jun-16-16 10:19AM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Jun-11-16 09:20AM  3 Biotechs That Just Announced Successful Phase 2 Trials at 24/7 Wall St.
Jun-09-16 08:15AM  Oramed to Present at the American Diabetes Association 76th Scientific Sessions PR Newswire +6.21%
May-23-16 05:14PM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure
May-18-16 03:00PM  ORMP: Oramed Announces Positive Top-Line Data from Phase IIb ORMD-0801 Study -7.97%
10:56AM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Other Events
09:23AM  Oramed's Phase IIb Oral Insulin Study Meets Primary Safety And Efficacy Endpoints
07:30AM  Oramed says oral insulin succeeds in midstage type 2 diabetes trial
07:25AM  Oramed Announces Positive Top-Line Results from Phase IIb Oral Insulin Study PR Newswire
May-16-16 09:49AM  Oramed to Present at Oppenheimer Annual Israeli Conference PR Newswire +27.60%
May-12-16 02:45PM  ORMP: Todays Decline In Share Price Not Justified -21.57%
May-11-16 08:15AM  Oramed Patent Being Granted in China for Oral Administration of Proteins PR Newswire
May-04-16 08:35AM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online +6.15%
Apr-28-16 08:15AM  Oramed to Present at PIONEERS 2016, Presented by Joseph Gunnar PR Newswire
Apr-12-16 08:15AM  Oramed Receives Patent Term Adjustment Extending the Term of Its U.S. Patent PR Newswire
Apr-07-16 11:30AM  ORMP: Update on Fiscal Second Quarter Financials
Apr-06-16 05:41PM  Oramed reports 2Q loss
03:30PM  ORAMED PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report
Apr-05-16 08:15AM  Oramed Completes Phase IIb Oral Insulin Study PR Newswire
Mar-29-16 07:10PM  Oramed Patent Granted in India for Oral Administration of Proteins at noodls +5.56%
08:15AM  Oramed Patent Granted in India for Oral Administration of Proteins PR Newswire
Feb-04-16 08:15AM  Oramed to Present at the BIO CEO & Investor Conference PR Newswire +8.48%
Jan-14-16 03:06PM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure
Jan-13-16 04:23PM  Oramed reports 1Q loss
01:12PM  ORAMED PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report
Jan-12-16 12:40PM  Oramed Pharma (ORMP): Great Potential for its Unique Protein Oral Delivery (POD) Platform
Jan-06-16 10:08AM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure
08:15AM  Oramed Pharmaceuticals' Shareholder Letter PR Newswire
Dec-29-15 08:15AM  Oramed Announces Closing of Licensing and Investment Deal with HTIT for Oral Insulin Capsule in China PR Newswire
Dec-28-15 04:33PM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Other Events
Dec-01-15 09:00AM  $50 Million Plus Royalties Deal Indicates Blockbuster Future for Oramed's Oral Insulin Accesswire
Nov-30-15 04:15PM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equi +17.42%
10:32AM  Oramed Pharmaceuticals (ORMP) Stock Surges on $50 Million Chinese Licensing Deal at TheStreet
08:16AM  Oramed Signs up to $50 Million Licensing and Investment Agreements for Oral Insulin Capsule in China PR Newswire
07:51AM  Israel's Oramed gets $50 mln China licensing, investment deal Reuters
Nov-25-15 01:39PM  ORAMED PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report
Nov-20-15 06:08AM  [$$] Oramed Could Double With Diabetes Blockbuster at Barrons.com +12.50%
Oct-26-15 05:04PM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Other Events +6.56%
Oct-15-15 03:51PM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Other Events
Oct-01-15 08:15AM  Oramed to Present at the Aegis Capital Growth Conference PR Newswire +6.40%
Sep-24-15 08:15AM  Oramed Patent Allowed in the US for Oral Administration of Proteins PR Newswire +14.53%
Sep-09-15 08:15AM  Oramed Completes Randomization of Over 50% of Patients in Phase IIb Oral Insulin Study PR Newswire
Sep-04-15 08:15AM  Oramed to Present at the Rodman & Renshaw Global Investment Conference PR Newswire
Sep-03-15 09:13AM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Other Events -6.31%
Aug-31-15 08:45AM  As Diabetes Becomes an Epidemic, Patients Seek the Best Treatment Options Accesswire
Aug-12-15 08:12AM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jul-21-15 08:00AM  Cell MedX Aiming to Change Diabetes Care Forever Accesswire
Jul-14-15 02:21PM  3 Stocks Under $10 to Trade for Breakouts at TheStreet
Jul-08-15 09:00AM  Oramed's Quick Road to Market as Global Leader of Oral Insulin Capsule Accesswire
Jul-07-15 09:17AM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Other Events
08:00AM  Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing Deal in China PR Newswire
Jul-06-15 08:51AM  Oramed Pharmaceuticals (ORMP) in Focus: Stock Up 19.2% - Tale of the Tape
Jul-02-15 04:36PM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure +19.21%
01:44PM  3 Stocks Under $10 Triggering Breakout Trades at TheStreet
Jul-01-15 03:12PM  ORAMED PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report
Jun-30-15 09:18AM  Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study PR Newswire
08:15AM  Oramed Submits Protocol to U.S. FDA for its Phase IIb Oral Insulin Study PR Newswire
Jun-16-15 08:15AM  Oramed Granted Patent in Russia for Oral Administration of GLP-1 PR Newswire
Jun-11-15 08:15AM  Oramed Announces Closing of $5.36 Million Registered Direct Offering PR Newswire -6.47%
Jun-05-15 01:16PM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and -6.87%
08:25AM  Oramed to Raise $5.36 Million in Registered Direct Offering PR Newswire
Jun-02-15 08:15AM  Oramed to Present at the American Diabetes Association 75th Scientific Sessions PR Newswire
May-27-15 06:05AM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
May-26-15 08:15AM  Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study PR Newswire
May-06-15 10:09AM  Oramed to Present at Upcoming Conferences at noodls -9.72%
May-05-15 09:25AM  Oramed to Present at Upcoming Conferences PR Newswire
Apr-29-15 03:39AM  Oramed Pharmaceuticals Inc. Issues Phase IIb Study Update Letter at noodls
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. The company operates primarily in Israel. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in Jerusalem, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KIDRON NADAVPresident and CEOMay 12Buy6.951,0006,953958,148May 12 05:28 PM